Drugs / SSGJ-608
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06299982 | May 2024 → Jan 2025 | psoriasis | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SSGJ-608 | “BACKGROUND: SSGJ-608 is an anti-interleukin-17A monoclonal antibody with high specificity and high affinity and has shown promising efficacy in treatment of moderate-to-severe...” PMID 42344898 ↗ Jun 2026 |
| Action | Inhibit | “SSGJ-608 is an anti-interleukin-17A monoclonal antibody” PMID 42344898 ↗ Jun 2026 |
| Modality | Monoclonal antibody | “SSGJ-608 is an anti-interleukin-17A monoclonal antibody” PMID 42344898 ↗ Jun 2026 |
| Route | Subcutaneous | “subcutaneous injections of 80mg of SSGJ-608 every two weeks” PMID 42344898 ↗ Jun 2026 |
| Target | IL17A | “anti-interleukin-17A” PMID 42344898 ↗ Jun 2026 |